Bronchodilators Market size, share, growth, trend, analysis, opportunity and forecast 2022-2028

Bronchodilators Market: Emphasis on Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others); Drug Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Phosphodiesterase Inhibitor, Combination Drugs, Others); Route of Administration (Oral, Injection, Inhaler) and Region/Country

Global Bronchodilators market is expected to register a CAGR of around ~5% over the period of 2021-2027. Bronchodilators are drugs that open up (dilate) the breathing passages by relaxing the bronchial smooth muscle.

They make breathing easier for people with asthma or other lung conditions. Thus, the increase in the number of patients with respiratory disorders, and the treatment of various diseases such as asthma, chronic obstructive pulmonary disease, and others.

The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma.

Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of patients, this is likely to boost the demand for bronchodilators in near future. Moreover, the surge in product approval and launches for treating asthma is further estimated to supplement the market growth.

For instance, in May 2019, Sanofi received European Commission approval for its ‘Dupixent’ used in treating patients with severe asthma. Therefore, the market for bronchodilators is expected to witness significant growth during the forecast period.  

 According to UnivDatos Market Insights (UMI)’ research report “global bronchodilators market”, the market is expected to witness robust growth during the forecast period 2021-2027F. The global bronchodilators market is experiencing significant growth due to the rising incidence rate of respiratory disorders, technological advancements, and changing lifestyles.

Request Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ univdatos.com/get-a-f…t_id=32402

Based on indication, the market is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. Among these, asthma is expected to witness the highest CAGR during the forecast period.

Asthma is a breathing disorder caused due to narrowing of airway passages within the lungs due to various causes such as muscle spasms, excess production of mucus, or swelling in the airway. Moreover, bronchodilators ease these symptoms of asthma by opening the airways and reducing the effects of an attack.

For instance, according to the world health organization (WHO), Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths.

Based on drug type, the market is categorized into beta-adrenergic bronchodilators, anticholinergic bronchodilators, phosphodiesterase inhibitors, combination drugs, and others. Among these, the anticholinergic bronchodilators are expected to witness the highest CAGR during the forecast period as it is widely used to treat chronic obstructive pulmonary disease.

In addition, Anticholinergic bronchodilators block the parasympathetic nerves and enable the air passages to remain open.

Browse Full Report Description + Research Methodology + Table of Content + [email protected] univdatos.com/report/…rs-market/

North America to witness extensive growth

For a better understanding of the market adoption of the Bronchodilators, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America accounted for a prominent share of the global bronchodilators market and is expected to grow at a significant growth rate during the forecast period owing to the quick adoption of bronchodilators technologies along with the high incidence of COPD and asthma cases.

The United States Environmental Protection Agency and the National Health Interview Surveys (NHIS), in April 2021, estimated that almost 25.1 million people, comprising 5.1 million children, have asthma in the country. Major healthcare companies are investing heavily in their products due to rising social awareness among healthcare industry experts, medical professionals, and patients about the benefits that bronchodilators have to prompt the regulatory authorities to consider and authorize the bronchodilators.

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the global Bronchodilators market are Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., SANOFI, Teva Pharmaceutical Industries Ltd., Vectura Group Plc are some of the key players in the market.

Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions.

Request For Customization- univdatos.com/get-a-f…t_id=32402

“Global Bronchodilators Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters.

This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.      

Market Segmentation:

1. By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others)
2. By Drug Type (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Phosphodiesterase Inhibitor, Combination Drugs, Others)
3. By Route of Administration (Oral, Injection, Inhaler)
4. By Region (North America, Europe, Asia-Pacific, Rest of the World)
5. By Company (Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., SANOFI, Teva Pharmaceutical Industries Ltd., Vectura Group Plc.)

   Get Sample PDF Brochure @ univdatos.com/get-a-f…t_id=32402

Key questions answered in the study:

1. What are the current and future trends of the global bronchodilators industry?
2. How the industry has been evolving in terms of technology and application?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the global bronchodilators industry?

What is the customer orientation, purchase behavior, and expectations from the global bronchodilators suppliers across various region and countries?

Table of Content- 

1 MARKET INTRODUCTION
2 RESEARCH METHODOLOGY OR ASSUMPTION
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 GLOBAL BRONCHODILATORS MARKET COVID-19 IMPACT
6 GLOBAL BRONCHODILATORS MARKET REVENUE (USD BN), 2019-2027F
7 MARKET INSIGHTS BY INDICATION
8 MARKET INSIGHTS BY DRUG TYPE
9 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION
10 MARKET INSIGHTS BY REGION
11 BRONCHODILATORS MARKET DYNAMICS
12 BRONCHODILATORS MARKET OPPORTUNITIES
13 BRONCHODILATORS MARKET TRENDS
14 POLICY & REGULATORY FRAMEWORK
15 DEMAND AND SUPPLY-SIDE ANALYSIS
16 VALUE CHAIN ANALYSIS
17 COMPETITIVE SCENARIO
18 COMPANY PROFILED
19 DISCLAIMER

This email address is being protected from spambots. You need JavaScript enabled to view it.